PALISADE BIO Sells Equity in Unregistered Offering
Ticker: PALI · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1357459
| Field | Detail |
|---|---|
| Company | Palisade Bio, Inc. (PALI) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $0.7313, $2,502,717, $40,000 |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: equity-offering, dilution, capital-raise
TL;DR
**PALI just sold more stock privately, likely diluting current shareholders.**
AI Summary
PALISADE BIO, INC. (PALI) entered into a material definitive agreement on January 30, 2024, involving the unregistered sale of equity securities. This 8-K filing, dated February 1, 2024, indicates the company is raising capital through private placement, which can dilute existing shareholders' ownership. This matters to investors because while it provides necessary funding for operations, it could negatively impact the per-share value of their investment.
Why It Matters
This filing signals that PALISADE BIO is raising capital, which is crucial for its operations but could dilute the value of existing shares for current investors.
Risk Assessment
Risk Level: medium — The unregistered sale of equity securities often leads to dilution for existing shareholders, which can negatively impact stock price.
Analyst Insight
A smart investor would monitor for further details on the terms of the unregistered equity sale to assess the extent of dilution and its potential impact on share price before making any investment decisions.
Key Players & Entities
- PALISADE BIO, INC. (company) — the registrant filing the 8-K
- January 30, 2024 (date) — date of the earliest event reported
- February 1, 2024 (date) — date of the 8-K report
- 001-33672 (other) — Commission File Number
Forward-Looking Statements
- PALISADE BIO, INC. will announce the specific terms (e.g., number of shares, price per share) of the unregistered equity sale. (PALISADE BIO, INC.) — medium confidence, target: 2024-03-31
- The stock price of PALISADE BIO, INC. (PALI) will experience downward pressure due to potential dilution. (PALISADE BIO, INC.) — medium confidence, target: 2024-02-29
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 30, 2024, as stated in the 'Date of Report (Date of earliest event reported): February 1, 2024 (January 30, 2024)' section.
What type of agreement did PALISADE BIO, INC. enter into?
PALISADE BIO, INC. entered into a 'Material Definitive Agreement' according to the 'ITEM INFORMATION: Entry into a Material Definitive Agreement' section.
What kind of securities were sold as reported in this filing?
The filing reports 'Unregistered Sales of Equity Securities' under the relevant ITEM INFORMATION section.
What is the business address of PALISADE BIO, INC.?
The business address of PALISADE BIO, INC. is 7750 El Camino Real Suite 2A, Carlsbad, California, 92009, as listed in the filing.
What is the telephone number for PALISADE BIO, INC.?
The registrant's telephone number, including area code, is (858) 704-4900, as provided in the filing.
Filing Stats: 1,349 words · 5 min read · ~4 pages · Grade level 12.9 · Accepted 2024-02-01 06:02:11
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share PALI Nasdaq Capital Mark
- $0.7313 — t is being exercised will be reduced to $0.7313 per share. Each Holder that exercises i
- $2,502,717 — ceiving gross proceeds of approximately $2,502,717, excluding closing costs and placement
- $40,000 — cement Agent Warrant"), and (iii) up to $40,000 of out-of-pocket expenses. The forego
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex4-01.htm (EX-4.01) — 131KB
- ex4-02.htm (EX-4.02) — 128KB
- ex10-01.htm (EX-10.01) — 51KB
- ex99-01.htm (EX-99.01) — 15KB
- ex99-01_001.jpg (GRAPHIC) — 9KB
- 0001493152-24-004539.txt ( ) — 627KB
- pali-20240201.xsd (EX-101.SCH) — 3KB
- pali-20240201_lab.xml (EX-101.LAB) — 33KB
- pali-20240201_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 1, 2024 Palisade Bio, Inc. /s/ J.D. Finley By: J.D. Finley Chief Executive Officer